Background
Epstein–Barr virus (EBV) is associated with the pathogenesis of a variety of malignancies, most notably lymphomas. Especially in the background of immunodeficiency, such as primary immunodeficiency disorder (PID) and post-transplant lymphoproliferative disorder (PTLD), the role of EBV might be crucial [
1]. PIDs are heterogeneous diseases affecting the development and/or the function of various components of the innate and adaptive immune system [
2]. The prevalence of PIDs is approximately 41–51:100,000. Malignancy is the second-highest cause of death after infection, and lymphoma accounts for approximately half of malignancies in both children and adults [
3,
4]. The risk of lymphoma increases up to 10 times in PID patients, and EBV is associated with 30–60% of lymphoma cases in PIDs [
4,
5]. In PIDs, the most frequently reported lymphoma types are diffuse large B-cell lymphoma (DLBCL; 33.5%) and Burkitt’s lymphoma (7.1%), but the incidence of T-cell lymphoma is rare [
1,
6,
7].
PTLDs are also rare serious lymphoid and/or plasmacytic proliferative disorders that occur after solid organ or hematopoietic stem cell transplantation (HSCT) [
8]. The incidence of PTLDs is 30–50 times higher than that in the general population and ranges from 2 to 10%, whereas the incidence of PTLDs after HSCT is less than 1% [
9,
10]. Most PTLDs are of B-cell origin and are related to EBV infection. T-cell PTLDs, in contrast, constitute fewer than 15% of PTLDs in Western countries [
11]. In the context of HSCT, most reported PTLDs have occurred in patients who received allogenic HSCT (AlloHSCT). However, only 25 published cases of PTLD following autologous HSCT (AutoHSCT) have been reported as case reports, with six cases having a T-cell origin reported (Table
1) [
12‐
32]. Here, as a unique case of metachronous B-cell and T-cell lymphoma, we report a rare case of T-cell lymphoma that mainly affected the lungs with notable granulomatous findings following AutoHSCT with sustained hypogammaglobulinemia against EBV-positive DLBCL at the age of 53 years.
Table 1
Summary of the clinicopathologic features of T-cell lymphoproliferative disorder following autologous hematopoietic stem cell transplantation
1 | 48 years | HL | (1) Doxorubicin-based chemotherapy (2) High-dose cytosine arabinoside (3) Conditioning regimen that included cyclophosphamide, etoposide, and ranimustine | T-cell PTLD | (Lymph node) Lymphoid hyperplasia with mild sinus histiocytosis, as well as proliferation of epithelioid cells. | Positive | Mesenteric lymph nodes | 2 years and 6 months | Fatal | |
2 | 61 years | AITL | (1) Four cycles of CHOP (2) High-dose etoposide (3) Two cycles of CHOP (4) Ranimustine, cyclophosphamide, etoposide, and carboplatin | T-LGL | (Blood) Pronounced lymphocytosis of large-sized lymphoid cells with round to indented nuclei, coarse chromatin, and azurophilic cytoplasmic granules. | Negative | Bone marrow | 1 month | Survival | |
3 | 62 years | FL | (1) Eight cycles of CHOP (2) Two cycles of MINE (3) Etoposide (4) Ranimustine, carboplatin, etoposide, and cyclophosphamide | AITL | (Lymph node) Diffuse infiltration of medium to large-sized lymphoid cells with predominant proliferation of small blood vessels. | Positive | Cervical and supraclavicular lymph nodes | 4 months | Resolved | |
4 | 49 years | AITL | (1) Five cycles of CHOP (2) Salvage chemotherapy: ESHAP (3) MCVAC | T-cell PTLD | (Autopsy) Lymphoid cells in the bone marrow, portal area of the liver, lymph nodes and lungs. The hypocellularity in the marrow with the proliferation of macrophages and marked hemophagocytosis. Macrophages in the marrow, liver, lymph nodes, and lungs. | Positive | Bone marrow, liver, lungs, lymph nodes | 3 months | Fatal | |
5 | 47 years | DLBCL | High-dose radiotherapy and chemotherapy | Enteropathy type T-cell lymphoma | (Jejunum) An atypical destructive lymphoid infiltration with intraepithelial lymphocytes in the superficial mucosa and in the glands. | Negative | Jejunum, duodenum, mesenteric lymph nodes | 6 years and 3 months | Resolved | |
6 | 53 years | MM | (1) Three cycles of VAD (2) High-dose melphalan: Prednisolone and cyclosporin A for erythroderma | AITL | (Lymph node) Nodular infiltration of atypical lymphocytes with large nucleoli. | Positive | Brain, axillary and inguinal lymph nodes | 10 months | Resolved | |
Our case | 53 years | DLBCL | (1) Six cycle of R-CHOP (2) Three cycles of R-ACES | PTCL-NOS | (Lung) Diffuse infiltration of small to medium-sized lymphocytes with multiple granulomas. | Positive | Supraclavicular, mediastinal, hilar, paraaortic, mesenteric lymph nodes, lungs | 4 years | Fatal | |
Discussion
We describe a case of T-cell lymphoma after chemotherapy and AutoHSCT for EBV-positive DLBCL as a unique rare case of metachronous B-cell and T-cell lymphoma. Our patient was diagnosed with EBV-positive DLBCL of the cervical LNs at the age of 53 years, and multiple lung lesions of PTCL-NOS associated notable granulomas were observed 4 years after complete remission following chemotherapy and AutoHSCT for DLBCL with sustained hypogammaglobulinemia.
EBV is etiologically linked to a remarkably wide range of lymphoproliferative lesions, including malignant lymphomas, as EBV-associated lymphoproliferative disorders (LPDs) [
33]. It was recently reported that EBV-associated LPDs could be categorized into two groups, including disorders in which the host is usually immunocompetent and the role of EBV might be secondary or essential in only a subset of patients such as DLBCL, and disorders that arise in patients with immunodeficiency in which the role of EBV might be crucial, such as LPD associated with PID or PTLD, etc. There is a strong association between the pattern of EBV latency and the immune status of the host, suggesting that the underlying immune condition and the microenvironment are essential for the pathogenesis and manifestations of lymphomas associated with EBV [
1].
Our patient developed EBV-positive DLBCL at the age of 53 years. EBV-positive DLBCL usually develops in individuals aged > 50 years, with a peak in the eighth decade [
34], thus the onset age of DLBCL of our case seemed relatively young. Our patient also showed sustained and progressive hypogammaglobulinemia with recurrent respiratory infections after R-CHOP for DLBCL. Because hypogammaglobulinemia has been recognized before AutoHSCT for DLBCL treatment, this condition could not be related to transplantation. Thus, the age of onset for EBV-positive DLBCL, hypogammaglobulinemia, and respiratory infections, which comprised the background of our case, led us to consider the possibility of underlying primary immunodeficiency, such as PID including common variable immunodeficiency (CVID).
Monogenic and other genetic defects of the immune system are categorized as PIDs, which affect various components of the immune system with susceptibility to infections but also to malignancies, including lymphoma [
2,
6,
35,
36]. Recent investigations reported that the risk of lymphoma is increased tenfold in PID patients and that EBV is associated with 30–60% of lymphoma cases in PIDs [
4,
5]. CVID is one of the most prevalent types of PIDs, occurring in approximately 1:50,000–1:25,000 individuals, and is typically characterized by significantly decreased serum levels of IgG with low IgA and/or IgM and recurrent bacterial infections [
37‐
39]. CVID is most often diagnosed in individuals between the ages of 20 and 40 years, however, can occur at any age [
37,
39].
In our case, there was indeed an EBV-positive DLBCL first occurring at the age of 53 years, with both IgG and IgA hypogammaglobulinemia at the initial diagnosis of DLBCL, as well as marked hypogammaglobulinemia that persisted and progressed for at least 4 years after DLBCL treatment until the onset of T-cell lymphoma with prominent granulomatous lesions. Therefore, a potential immune deficiency, such as CVID, cannot be ruled out in our case as one of the causes of this unique duplex T-cell after B-cell lymphoma.
In our case, metachronous tumor of T-cell lymphoma occurred and mainly affected the lungs 4 years after AutoHSCT for EBV-positive DLBCL, and thus, our case could be regarded as T-cell PTLD. PTLDs are lymphoid and/or plasmacytic proliferation disorders, including lymphoma, which develop as a consequence of immunosuppression after transplantation [
8,
40]. In the context of HSCT, most cases of PTLD are reported in patients who received AlloHSCT and the incidence of PTLDs after AlloHSCT is less than 1% [
9,
10]. Moreover, to the best of our knowledge, only 25 published cases of PTLD following AutoHSCT have been reported as case reports, with six cases of T-cell origin after AutoHSCT [
12‐
32]. Thus our case could be regarded as a very rare case of T-cell PTLD after AutoHSCT. We reviewed the clinicopathological data of seven previously reported cases of T-cell PTLD after AutoHSCT including this case and found that five of seven (71.4%) cases were EBV infection-positive and two of seven (28.6%) cases had macrophage proliferative lesions (Table
1). Therefore, although EBV-positive findings in our case were considered relatively low, the possibility that EBV infection has some influence on the development of T-cell lymphoma in our case cannot be completely ruled out, in addition to the possibility that background immunodeficiency might have been involved. However, the most recent WHO classification of lymphoid neoplasms favors these rarely reported lesions of PTLD after AutoHSCT as being more likely iatrogenic and related to the therapy than related to the transplant itself [
8]. Thus, we can use the term “PTLD-like lesion” for the T-cell lymphoma lesion in our case, if we use the term “PTLD”.
In our case, the VATS specimen showed notable lymphocyte infiltration and multiple granulomas. No clinicopathological cause of the granuloma was found such as tuberculosis, fungal infection, sarcoidosis, or granulomatous angiitis. As a differential diagnosis, the granulomatous findings can be cited as being related to Lennert’s lymphoma (LeL), a rare variant of PTCL-NOS, characterized by prominent small clusters of epithelioid histiocytes [
41,
42]. However, LeL was reported to comprise only 0.71% of PTCLs and relatively rarely invades the extranodal foci; therefore, this pulmonary lesion is not considered a typical LeL-related finding [
43,
44]. In contrast, considering hypogammaglobulinemia in our patient, these granulomatous findings could also be interpreted as histological changes associated with the underlying immunodeficiency of this case, as mentioned previously, in addition to a PTCL-NOS lesion. This is because recent studies reported that 1–4% of PID patients have granulomas and the most common types of granulomas are sino-pulmonary (50%), hematologic-lymphoid (33%), and skin (16%); further, 42% are considered to have prominent granulomas [
45].
In conclusion, we report a rare case of T-cell lymphoma mainly affecting the lungs with notable granulomatous findings that developed post-AutoHSCT for EBV-positive DLBCL as a unique case of metachronous B-cell and T-cell lymphoma. These lung lesions of granulomatous T-cell lymphoma could be related to an underlying primary immunodeficiency background associated with sustained hypogammaglobulinemia.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.